Key statistics
On Monday, Immunitybio Inc (26CA:MUN) closed at 9.01, -13.26% below its 52-week high of 10.39, set on Feb 25, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.39 |
|---|---|
| High | 9.01 |
| Low | 8.03 |
| Bid | 8.86 |
| Offer | 8.96 |
| Previous close | 8.07 |
| Average volume | 191.71k |
|---|---|
| Shares outstanding | 1.03bn |
| Free float | 373.46m |
| P/E (TTM) | -- |
| Market cap | 10.05bn USD |
| EPS (TTM) | -0.3898 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 15:18 GMT.
More ▼
Press releases
- ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
- ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
- ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
- ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
- ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
- ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
- ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
- ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
- ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
- ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
More ▼
